<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue journalpublishing.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Vis</journal-id><journal-id journal-id-type="publisher-id">MV</journal-id><journal-title-group><journal-title>Molecular Vision</journal-title></journal-title-group><issn pub-type="epub">1090-0535</issn><publisher><publisher-name>Molecular Vision</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">22</article-id><article-id pub-id-type="publisher-id">2009MOLVIS0353</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Alu-element insertion in an <italic>OPA1</italic> intron sequence associated with autosomal dominant optic atrophy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gallus</surname><given-names>Gian Nicola</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cardaioli</surname><given-names>Elena</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rufa</surname><given-names>Alessandra</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Da Pozzo</surname><given-names>Paola</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bianchi</surname><given-names>Silvia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>D&#x02019;Eramo</surname><given-names>Camilla</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Collura</surname><given-names>Michele</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tumino</surname><given-names>Manuela</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pavone</surname><given-names>Lorenzo</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Federico</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><aff id="aff1"><label>1</label>Department of Neurological, Neurosurgical and Behavioural Sciences, University of Siena, Siena, Italy</aff><aff id="aff2"><label>2</label>Italian Union of the Blind, Siracusa, Italy</aff><aff id="aff3"><label>3</label>Department of Pediatric, University of Catania, Catania, Italy</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to: Antonio Federico, Department of Neurological, Neurosurgical and Behavioural Sciences, University of Siena, Viale Bracci 2, 53100 Siena, Italy; Phone: 39-577-585763; FAX: 39-577-40327; email: <email xlink:href="federico@unisi.it">federico@unisi.it</email></corresp></author-notes><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>10</day><month>2</month><year>2010</year></pub-date><volume>16</volume><fpage>178</fpage><lpage>183</lpage><history><date date-type="received"><day>12</day><month>10</month><year>2009</year></date><date date-type="accepted"><day>05</day><month>2</month><year>2010</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2010 Molecular Vision.</copyright-statement><copyright-year>2010</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Purpose</title><p>Autosomal dominant optic atrophy (ADOA) is the most common form of hereditary optic neuropathy caused by mutations in the optic atrophy 1 (<italic>OPA1)</italic> gene. It is characterized by insidious onset with a selective degeneration of retinal ganglion cells, variable loss of visual acuity, temporal optic nerve pallor, tritanopia, and development of central, paracentral, or cecocentral scotomas. Here we describe the clinical and molecular findings in a large Italian family with ADOA.</p></sec><sec><title>Methods</title><p>Routine ophthalmologic examination and direct sequencing of all coding regions of the <italic>OPA1</italic> gene were performed. Further characterization of a new <italic>OPA1</italic> gene insertion was performed by reverse transcription-PCR (RT&#x02013;PCR) of RNA from patients and control subjects.</p></sec><sec><title>Results</title><p>We identified an Alu-element insertion located in intron 7 of <italic>OPA1</italic> causing an in-frame deletion of exon 8 in 18 family members.</p></sec><sec><title>Conclusions</title><p>The predicted consequence of this mutation is the loss of the guanosine triphosphatase (GTPase) activity of OPA1. Alu insertions have been reported in the literature as causing human genetic disease. However, this is the first report of a pathogenic <italic>OPA1</italic> gene mutation resulting from an Alu insertion.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>GalleyStatus</meta-name><meta-value>Export to XML</meta-value></custom-meta><custom-meta><meta-name>corr-author</meta-name><meta-value>Federico</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Autosomal dominant optic atrophy (ADOA; OMIM <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=165500">165500</ext-link>) is the most common form of hereditary optic neuropathy, with an estimated prevalence between 1:10,000 and 1:50,000 in different populations [<xref ref-type="bibr" rid="r1">1</xref>]. It is characterized by insidious onset with a selective degeneration of retinal ganglion cells, variable loss of visual acuity, temporal optic nerve pallor, tritanopia, and development of central, paracentral, or cecocentral scotomas [<xref ref-type="bibr" rid="r2">2</xref>]. ADOA is inherited in an autosomal dominant manner with high interfamilial and intrafamilial phenotypic variability and incomplete penetrance.</p><p>Mutations in the optic atrophy 1 (<italic>OPA1)</italic> gene (that consists of 30 coding exons) are responsible for approximately 90% of cases. <italic>OPA1</italic> encodes a large guanosine triphosphatase (GTPase), implicated in the formation and maintenance of the mitochondrial network [<xref ref-type="bibr" rid="r3">3</xref>] and in protection against apoptosis by segregating cytochrome <italic>c</italic> inside the mitochondrial cristae [<xref ref-type="bibr" rid="r4">4</xref>]. OPA1 comprises a highly basic N-terminus, a dynamin GTPase domain, and a C-terminus. More than 200 pathogenic mutations have been reported in the literature (see the <ext-link ext-link-type="uri" xlink:href="http://lbbma.univ-augers.fr/eOPA1">eOPA1 database</ext-link>). No significant correlation has been observed between degree of visual impairment and location or type of mutation [<xref ref-type="bibr" rid="r5">5</xref>]. Missense mutations in <italic>OPA1</italic>, however, leading to multiple mitochondrial DNA (mtDNA) deletions in skeletal muscle and a mosaic defect of cytochrome <italic>c</italic> oxidase, were recently found. In these cases the disorder presented with visual failure and optic atrophy in childhood, followed by Progressive External Ophthalmoplegia (PEO), ataxia, deafness, and sensory-motor neuropathy in adulthood. Moreover, some cases show additional neurologic symptoms, the so-called optic atrophy <italic>plus</italic> phenotypes [<xref ref-type="bibr" rid="r6">6</xref>].</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Family study</title><p>Twenty-eight individuals of a single large Italian family were recruited from the Department of Neurologic, Neurosurgical and Behavioral Sciences of Siena, the Italian Union of the Blind of Siracusa and the Department of Pediatric of Catania. There were 15 females and 13 males ranging in age from 9 to 59 years. We use the term &#x0201c;family&#x0201d; to indicate descendants of a multigenerational pedigree of related individuals (<xref ref-type="fig" rid="f1">Figure 1</xref>). Autosomal dominant inheritance was indicated by multiple affected individuals in each generation. All patients underwent routine ophthalmologic examination, including visual acuity, color vision, manual visual field, slit-lamp examination, intraocular pressure (IOP), and dilated fundoscopy. Clinical neurologic examination and genetic analysis was also performed in all patients.</p><fig id="f1" fig-type="figure" position="float"><label>Figure 1</label><caption><p>Pedigree diagram of the Autosomal Dominant Optic Atrophy (ADOA) family. The pedigree of a five-generation family shows eighteen affected members. Solid squares mean male patients, open circles mean normal females, solid circles mean female patients, open squares mean normal males, arrow means proband (V-3). Oblique lines through circles and squares represent deceased, vertical lines indicate the presence of the mutation in two unaffected family members (IV-7 and IV-10) and in another family member not available for ophthalmological examination (V-15).</p></caption><graphic xlink:href="mv-v16-178-f1"/></fig></sec><sec><title>Mutation analysis</title><p>After informed consent was obtained, 5&#x000a0;ml of blood from the proband, his family members, and healthy controls, was drawn into an ethylenediamine tetraacetic acid (EDTA) sample tube and preserved (frozen). Genomic DNA was extracted from blood samples using a QIAamp DNA blood kit (Qiagen, Limburg, Netherlands). All 30 coding exons (comprising intron&#x02013;exon boundaries) were amplified by PCR using primers specific for <italic>OPA1</italic> (<xref ref-type="table" rid="t1">Table 1</xref>). PCR reactions were performed in 25&#x000a0;&#x003bc;l reaction volumes containing 100 ng genomic DNA, 10 pmol forward and reverse primers, 100&#x000a0;mM dNTPs, 1U DNA polymerase (Eurotaq DNA polymerase; Euroclone, Milan, Italy), 1.5&#x000a0;mM MgSO<sub>4</sub>, 1&#x000d7; Reaction buffer, using a DNA thermal cycler (PTC-200; MJ Research, Waltham, MA). The PCR products of exon 8 were cloned into a PCR Cloning Vector pSC-A using the Strata Clone&#x02122; PCR Cloning Kit (Agilent Technologies, Stratagene Products Division, Santa Clara, CA). After purification of PCR products with QIAquick PCR Purification kits (Qiagen), sequencing was performed using the automated sequencer ABI 3730 (Applied Biosystems, Foster City, CA).</p><table-wrap id="t1" position="float"><label>Table 1</label><caption><title>DNA sequence of oligonucleotides used for polymerase chain reaction (PCR).</title></caption><table frame="hsides" rules="groups"><col width="68" span="1"/><col width="221" span="1"/><col width="226" span="1"/><col width="64" span="1"/><col width="74" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Amplified fragment</bold></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Forward primer (5&#x02032;-3&#x02032;)</bold></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Reverse primer (5&#x02032;-3&#x02032;)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>PCR length (bp)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Annealing temperature &#x000b0;C</bold></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Promotor<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CATGGCTAGTACGGATGTAATT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GGAGAAACTAACCACCATCA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">250<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">55<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TGTTTCCGTGACGGACTGAGTA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CCTGAGAGTCACCTGCACATTT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">330<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">56<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TCCTTTGTACTGTTACCCTCTC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CTAGTCCATGGTAGAGACACAA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">530<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">54<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CATTATTCTTAGTAGATTAATGTG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AAACAGTTAGTGGCAGCTGTGG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">340<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">56<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GTAGGGTTGTCATGAGGATTAA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CCTCCATGGTTCTTAAATTT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">270<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">54<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 4b<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GAAATCTGAGATCTCAGACATC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TGGTCTGCAATTTTATTTGCAAC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">250<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">57<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TCAGCTTAGGCTGTTGACATCAC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CCAGAACTGCCACGTAATACCT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">300<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">62<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 5b<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TCCCTAGCTTACATCTGTTCCT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TGGCAGAAATGGCTGATTAGTG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">270<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">57<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GCAACAGGGAAATGATTGCCTT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AGGTTCTATCATTACACCTTCC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">410<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">56<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AGGAGATATGACTTCAAGATTTTGG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CCATCCTCCAAGCACATTAGGTT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">350<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">57<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Intron 7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AGGAGATATGACTTCAAGATTTTGG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CATGTTTGTTAAGCTAGAACTG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">900<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">56<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Intron 7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CTGCAGTAAATCATGGCATGT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GAGAGAGAAAGAGAGAGGACAG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">650<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">52<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Intron 7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CAGTGGATACTTAACCACCC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GAGAACATCAAGAACTTCAG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">450<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">54<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CTCTTGACACATCTGTTATATT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GCCTACATCTAGTATGTATA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">270<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">52<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CTCAGAGCAGCATTACAAATAGG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AACACAATGAACAGGTCTCACTG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">250<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">57<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 10<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CAATGCAGTAGCCCTGTCTAGA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GGCTAACGGTACAGCCTTCTTT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">380<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">62<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 11<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GATAGTTCTCGGGAGTTTGATC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GCTCTACATATCTAGATAGCAGC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">360<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">62<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 12 and 13<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GTCTTATCTGAATGGATGAG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GCAAAGCTTGGATTGCTAAAGAAG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">420<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">57<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 14<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CTTGCTATAATGTAGACACAGGG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AAATCCCTATCACAGCTGGAGC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">300<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">62<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 15 and 16<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TAGGCAGCAGAGCAGGAATTCA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CAGTTCAATTTAAGCTACTCTC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">400<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">56<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 17<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AGCACATTCGCAGACTTGGTGGTA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GTATGGATGCCAAAGATTGCCAGC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">260<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">68<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 18<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CCACTTTAACCACTACATCTGG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GAGATAACTGCTCCTAGAGATG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">300<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">62<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 19<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CCTCCCTTTGGTTATCTCTGAA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GCCTATGAGCCAAGGCAACAATAAAT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">270<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">54<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 20<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CTTGACTGGTGCGATTTACAGG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GAAAGATAGAGGCTGTGATGGG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">430<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">60<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 21<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CTGTTTGGCTTGAGCTCGTGTT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TGAGGCTGATACCCCAGTATAC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">430<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">62<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 22<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GGGCCAGGAGAGAATCTCCACT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TGGATGACTCCTTCACCACTGT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">350<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">62<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 23<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CTGCCTTCATATTGATATAGCAC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">ATTCCTGAGACTGGTCTAGAGC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">300<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">54<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 24<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TTTACCATATTCATAAGCCGGG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TGTCAGCAAATGTACACGTGAC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">450<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">60<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 25<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CTTCTCAGTGTGGTTGATCAAC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CCCCAGATGATCAAAGGACTTA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">300<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">50<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 26<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CTGGTTCTAGTAGTTGTATGTG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AGCTACCACACCTGGCCAGTTT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">350<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">56<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 27<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GCACTTCCATTAAAGTGTATAGC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">ACAAATGGAAATGGGAAAGGTGG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">420<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">62<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon 28</td><td valign="top" align="left" rowspan="1" colspan="1">AAGGTGGTATGGTGAGACTCAT</td><td valign="top" align="left" rowspan="1" colspan="1">TACAGCATAAGTGACAAGCAGG</td><td valign="top" align="center" rowspan="1" colspan="1">350</td><td valign="top" align="center" rowspan="1" colspan="1">62</td></tr></tbody></table></table-wrap></sec><sec><title>Reverse Transcriptase&#x02013;PCR analysis</title><p>Peripheral blood, about 10&#x000a0;ml, was collected using vacutainer EDTA tubes (Becton-Dickinson, Franklin Lakes, NJ) from the proband (V-3, <xref ref-type="fig" rid="f1">Figure 1</xref>), the proband&#x02019;s mother (IV-8, <xref ref-type="fig" rid="f1">Figure 1</xref>) and three healthy controls. Total RNA was extracted from peripheral blood leucocytes using the LeukoLOCK&#x02122; Total RNA Isolation System following the instruction supplied by the manufacturer (Ambion, Austin, TX). The amount of total RNA extracted from each blood sample was quantified using the NanoDrop ND-1000 photometer (NanoDrop Technologies, Wilmington, DE). For each sample, 1.0&#x000a0;&#x003bc;g of total RNA was reverse transcribed with Affinity Script (Agilent Technologies) using oligo dT primers. PCR amplifications were performed with primers AF1 (5&#x02032;-GAC CAA CTT CAG GAA GAA CT-3&#x02032;) and AR1 (5&#x02032;-TGA GGA CCT TCA CTC AGA GT-3&#x02032;). After the purification of cDNA products with QIAquick PCR Purification kits (Qiagen), sequencing was performed using the automated sequencer ABI 3730.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Clinical findings in carriers of mutations</title><p>Neurologic examination was unremarkable (<xref ref-type="table" rid="t2">Table 2</xref>). Ophthalmologic examination revealed visual acuity ranging from 20/20 to less than 20/200. Color vision was normal in two subjects, the other 16 had different degrees of color sensitivity deficiency (eight of them showed generalized color sensitivity deficit). IOP with applanation was in the normal range in 11 patients (not exceeding 19&#x02013;20&#x000a0;mmHg); four subjects had IOP over 20&#x000a0;mmHg. One patient had high IOP (40&#x000a0;mmHg). Optic nerve appearance was normal in two subjects, whereas nine showed temporal pallor and six diffuse neurorim pallor.</p><table-wrap id="t2" position="float"><label>Table 2</label><caption><title>Patients clinical findings.</title></caption><table frame="hsides" rules="groups"><col width="41" span="1"/><col width="36" span="1"/><col width="50" span="1"/><col width="44" span="1"/><col width="64" span="1"/><col width="4" span="1"/><col width="60" span="1"/><col width="54" span="1"/><col width="45" span="1"/><col width="180" span="1"/><col width="64" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Case</bold><hr/></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Age</bold><hr/></th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1"><bold>Visual acuity</bold><hr/></th><th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1"><bold>Color vision Ishihara</bold><hr/></th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1"><bold>IOP applanation (mmHg)</bold><hr/></th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1"><bold>Ophthalmoscopy</bold><hr/></th></tr><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>&#x000a0;</bold></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>&#x000a0;</bold></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>RE</bold></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>LE</bold></th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1"><bold>RE</bold></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>LE</bold></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>RE</bold></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>LE</bold></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>RE</bold></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>LE</bold></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">III-3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">59<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20/40<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20/50<hr/></td><td colspan="3" valign="top" align="left" rowspan="1">2/15<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">18<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">diffuse neurorim pallor C/D 0.3<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">III-9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">58<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">&#x0003c;20/200<hr/></td><td colspan="3" valign="top" align="left" rowspan="1">generalized deficit<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">16<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">temporal pallor C/D 0.6&#x02013;0.7<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">III-11<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">56<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">&#x0003c;20/200<hr/></td><td colspan="3" valign="top" align="left" rowspan="1">generalized deficit<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">20<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">optic atrophy C/D 0.6&#x02013;0.7<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">III-13<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">51<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">&#x0003c;20/200<hr/></td><td colspan="3" valign="top" align="left" rowspan="1">generalized deficit<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">14<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">temporal pallor C/D 0.6&#x02013;0.7<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">IV-4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">41<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;20/200<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20/15<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3/15<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">40<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">optic atrophy C/D 0.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">subatrophy C/D 0.4<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">IV-7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">20/20<hr/></td><td colspan="3" valign="top" align="left" rowspan="1">15/15<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">21<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">&#x0003e;cupping C/D 0.5&#x02013;0.6<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">IV-8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">38<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">20/20<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">12/15<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">15/15<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">19<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">22<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">slight temporal pallor C/D 0.5&#x02013;0.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">cupping CD0.6&#x02013;0.7<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">IV-10<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">36<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">20/20<hr/></td><td colspan="3" valign="top" align="left" rowspan="1">15/15<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">normal<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">normal<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">IV-22<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">33<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20/40<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20/70<hr/></td><td colspan="3" valign="top" align="left" rowspan="1">generalized deficit<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">14<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">temporal pallor C/D 0.6&#x02013;0.7<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">IV-26<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">25<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">&#x0003c;20/200<hr/></td><td colspan="3" valign="top" align="left" rowspan="1">generalized deficit<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">16<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">temporal pallor C/D 0.3&#x02013;0.4<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">IV-27<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">27<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">&#x0003c;20/200<hr/></td><td colspan="3" valign="top" align="left" rowspan="1">generalized deficit<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">16<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">temporal pallor C/D 0.3&#x02013;0.4<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">IV-28<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">41<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">20/70<hr/></td><td colspan="3" valign="top" align="left" rowspan="1">4/15<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">16<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">17<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">diffuse neurorim pallor C/D: 0.4<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">IV-30<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">48<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20/70<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20/100<hr/></td><td colspan="3" valign="top" align="left" rowspan="1">generalized deficit<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">15<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">normal cupping<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">V-1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">20/40<hr/></td><td colspan="3" valign="top" align="left" rowspan="1">4/15<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">np<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">temporal pallor C/D 0.3<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">V-3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">20/100<hr/></td><td colspan="3" valign="top" align="left" rowspan="1">generalized deficit<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">np<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">temporal pallor C/D 0.7<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">V-12<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">20/20<hr/></td><td colspan="3" valign="top" align="left" rowspan="1">15/15<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">normal<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">slight temporal pallor. Normal cupping<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">V-14<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">17<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">20/50<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12/15<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">10/15<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">18<hr/></td><td colspan="2" valign="top" align="left" rowspan="1">diffuse neurorim pallor<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">V-15</td><td valign="top" align="left" rowspan="1" colspan="1">21</td><td colspan="2" valign="top" align="left" rowspan="1">N.A.</td><td colspan="3" valign="top" align="left" rowspan="1">N.A.</td><td colspan="2" valign="top" align="left" rowspan="1">N.A.</td><td colspan="2" valign="top" align="left" rowspan="1">N.A.</td></tr></tbody></table><table-wrap-foot><p>The phenotypic features of seventeen family members with <italic>OPA1</italic> mutation are shown. The numbering of patients in the first column is the same as in <xref ref-type="fig" rid="f1">Figure 1</xref>. The second column indicates age at diagnosis (in years). The fourth column indicates results of the Ishihara color test (a test for color blindness). The fifth column indicates intra-ocular pressure with applanation. Abbreviations: C/D represents cup to disk ratio; IOP represents intra-ocular pressure; RE represents right eye; LE represents left eye; N.P. represents not performed; N.A. represents not available.</p></table-wrap-foot></table-wrap></sec><sec><title>Molecular studies</title><p>We sequenced the 30 coding exons of <italic>OPA1</italic> in the propositus. We did not find any known pathogenic mutation, but amplification of exon 8 revealed a hemizygous product of about 604 bp (<xref ref-type="fig" rid="f2">Figure 2, A</xref>). Cloning and sequencing of the longer band revealed an insertion of about 325 bp. Using <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/BLAST/">BLAST</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://ftp.genome.washington.edu/">Repeat Masker</ext-link> [<xref ref-type="bibr" rid="r7">7</xref>] to elucidate the nature of the inserted fragment, we identified 289 bp of the insert as belonging to AluYb8 (99.65% homology with Alu Sb2). The Alu insert was composed of a 289-bp fragment and contained a 25-bp poly(A) tail at its 3&#x02032; end with perfect direct repeats of 17 bp flanking the insert (<xref ref-type="fig" rid="f2">Figure 2B,C</xref>). In <xref ref-type="fig" rid="f2">Figure 2C</xref> RNA polymerase III promoter (A and B boxes) and the consensus target site sequence are also indicated. The same mutation was found in 17 family members (<xref ref-type="fig" rid="f1">Figure 1</xref>); in ten subjects the mutation was absent, and the analysis was not performed in the remaining family members. The Alu insertion was located in intron 7 of <italic>OPA1</italic>, 21 bp upstream of exon 8, near the acceptor site (C.784&#x02013;21_22). The mutation caused the skipping of exon 8 in mRNA (<xref ref-type="fig" rid="f2">Figure 2D,E</xref>).</p><fig id="f2" fig-type="figure" position="float"><label>Figure 2</label><caption><p><italic>OPA1</italic> mutation in the Autosomal Dominant Optic Atrophy (ADOA) family. <bold>A</bold> shows the agarose gel of products from polymerase chain reaction (PCR) of exon 8. Lane 1 is patient sample (V-3), lanes 2 and 3 are normal controls, lane 4 is patient&#x02019;s mother (IV-8). <bold>B</bold> shows comparison of sequences of allele with Alu insertion and normal allele. Exon sequence is shown in bold and highlighted in sky blue; direct repeats flanking the Alu insertion are shown in bold and underlined; Alu element with poly(A) tail is highlighted in yellow; arrows in the normal sequence indicate the cuts. <bold>C</bold> shows complementary and reverse sequence of mutated region in <italic>OPA1</italic> gene with sequence elements of the Alu repeat. Consensus target site is shown in red bold characters and underlined; target-site duplications of the <italic>OPA1</italic> gene sequence flanking the integrated DNA are highlighted in sky blue; A and B box sequences (RNA polymerase III promoter) are highlighted in green and violet, respectively; poly(A) tail is highlighted in yellow. <bold>D</bold> shows the agarose gel of products from reverse transcription&#x02013;PCR of exons 6&#x02013;10 of the <italic>OPA1</italic> gene. Lane 1 is patient sample (V-3), lanes 2, 3, and 4 are normal controls. <bold>E</bold> shows electropherogram section with the skipping of exon 8.</p></caption><graphic xlink:href="mv-v16-178-f2"/></fig></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>In the case reported here, we found an unusual molecular defect in <italic>OPA1</italic> causing ADOA in a large Italian family. The defect is the result of an Alu element insertion.</p><p>Alu sequences are the most frequent, short, interspersed elements in the human genome, numbering 1.1 million copies and more than 10% of the mass of the genome. Alu elements are sequences of approximately 300 nucleotides flanked by perfect direct repeats of the host sequence, consistent with insertion into staggered nicks in the target DNA [<xref ref-type="bibr" rid="r8">8</xref>]. Alu and other repetitive elements have had great influence on the human genome and its evolution [<xref ref-type="bibr" rid="r9">9</xref>]. They influence mRNA splicing, RNA editing, and protein translation [<xref ref-type="bibr" rid="r10">10</xref>]. Not surprisingly, Alu insertions have been associated with several human genetic disorders. A total of 26 L1 trans-driven Alu insertions have so far been described as causes of diseases [<xref ref-type="bibr" rid="r11">11</xref>].</p><p>In our case the Alu element was inserted in the antisense direction with respect to <italic>OPA1</italic>. Alu element insertions in introns can have strong effects on gene expression, especially when inserted in the antisense direction. Five reports indicate that Alu insertions into intronic sequences in antisense orientation and close to the affected exon (19&#x02013;50 nucleotides) cause the downstream exon to shift from constitutive splicing to full exon skipping or alternative splicing. Three have been found to cause skipping of downstream exons: one impairs correct recognition of the splice acceptor site (<italic>F8</italic> gene) [<xref ref-type="bibr" rid="r12">12</xref>], while the other two may affect the branch site that is usually very close to the end of the intron (<italic>NF1</italic> and <italic>TNFRSF6</italic> genes) [<xref ref-type="bibr" rid="r13">13</xref>,<xref ref-type="bibr" rid="r14">14</xref>]. The orientation and position of the Alu in the upstream intron was recently studied. Lev-Maor et al. shed light on the positive and negative effects of Alu elements inserted in antisense orientation immediately upstream of the regulated exon [<xref ref-type="bibr" rid="r15">15</xref>].</p><p>In our case Alu insertion probably interferes with the branch site leading to production of an alternatively spliced mRNA lacking exon 8. Loss of this exon may be similar to that reported for Alu element insertion in <italic>NF1</italic> and <italic>TNFRSF6</italic> genes.</p><p>A consensus target site is probably generated in the antisense strand where integration of the retroposon begins: the first 5&#x02032;-gtAAAA-3&#x02032; hexanucleotides (3&#x02032;CA&#x02193;TTTT 5&#x02032;) of the 17-bp target-site duplication flanking the Alu element matches one of the more frequent consensus sequences perfectly [<xref ref-type="bibr" rid="r16">16</xref>]. The sense strand is nicked 17 bp from gtAAAA [<xref ref-type="bibr" rid="r17">17</xref>].</p><p>Phenotypic expression of this new mutation did not show particular peculiarities since ophthalmologic variability observed in our patients has also been described in other common <italic>OPA1</italic> mutations. Moreover, the presence of the mutation in two unaffected family members suggests incomplete penetrance, as previously reported for other <italic>OPA1</italic> gene mutations [<xref ref-type="bibr" rid="r18">18</xref>].</p><p>In conclusion, we describe an AluYb8 [<xref ref-type="bibr" rid="r8">8</xref>] retrotransposition event in an intron of the <italic>OPA1</italic> gene leading to exon skipping. The predicted consequence of this mutation is the loss of the GTPase activity of OPA1. Alu insertions have been reported in the literature as causing human genetic disease. However, this is the first report of a pathogenic <italic>OPA1</italic> gene mutation resulting from an Alu insertion.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank Professor Jerzy Jurka for helpful suggestions on retroposon integration mechanisms, all&#x000a0;patients, and Dr. Anna Rubegni for helping with the preparation of this manuscript. This work was supported by a grant from Regione Toscana and Monte dei Paschi Foundation to AF.</p></ack><ref-list><title>References</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kjer</surname><given-names>B</given-names></name><name><surname>Eiberg</surname><given-names>H</given-names></name><name><surname>Kjer</surname><given-names>P</given-names></name><name><surname>Rosenberg</surname><given-names>T</given-names></name></person-group><article-title>Dominant optic atrophy mapped to chromosome 3q region. II. Clinical and epidemiological aspects.</article-title><source>Acta Ophthalmol Scand</source><year>1996</year><volume>74</volume><fpage>3</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8689476</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carelli</surname><given-names>V</given-names></name><name><surname>Ross-Cisneros</surname><given-names>FN</given-names></name><name><surname>Sadun</surname><given-names>AA</given-names></name></person-group><article-title>Mitochondrial dysfunction as a cause of optic neuropathies.</article-title><source>Prog Retin Eye Res</source><year>2004</year><volume>23</volume><fpage>53</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">14766317</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delettre</surname><given-names>C</given-names></name><name><surname>Lenaers</surname><given-names>G</given-names></name><name><surname>Pelloquin</surname><given-names>L</given-names></name><name><surname>Belenguer</surname><given-names>P</given-names></name><name><surname>Hamel</surname><given-names>CP</given-names></name></person-group><article-title>OPA1 (Kjer type) dominant optic atrophy: a novel mitochondrial disease.</article-title><source>Mol Genet Metab</source><year>2002</year><volume>75</volume><fpage>97</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">11855928</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frezza</surname><given-names>C</given-names></name><name><surname>Cipolat</surname><given-names>S</given-names></name><name><surname>Martins de Brito</surname><given-names>O</given-names></name><name><surname>Micaroni</surname><given-names>M</given-names></name><name><surname>Beznoussenko</surname><given-names>GV</given-names></name><name><surname>Rudka</surname><given-names>T</given-names></name><name><surname>Bartoli</surname><given-names>D</given-names></name><name><surname>Polishuck</surname><given-names>RS</given-names></name><name><surname>Danial</surname><given-names>NN</given-names></name><name><surname>De Strooper</surname><given-names>B</given-names></name><name><surname>Scorrano</surname><given-names>L</given-names></name></person-group><article-title>OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion.</article-title><source>Cell</source><year>2006</year><volume>126</volume><fpage>177</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">16839885</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puomila</surname><given-names>A</given-names></name><name><surname>Huoponen</surname><given-names>K</given-names></name><name><surname>M&#x000e4;ntyj&#x000e4;rvi</surname><given-names>M</given-names></name><name><surname>H&#x000e4;m&#x000e4;l&#x000e4;inen</surname><given-names>P</given-names></name><name><surname>Paananen</surname><given-names>R</given-names></name><name><surname>Sankila</surname><given-names>EM</given-names></name><name><surname>Savontaus</surname><given-names>ML</given-names></name><name><surname>Somer</surname><given-names>M</given-names></name><name><surname>Nikoskelainen</surname><given-names>E</given-names></name></person-group><article-title>Dominant optic atrophy: correlation between clinical and molecular genetic studies.</article-title><source>Acta Ophthalmol Scand</source><year>2005</year><volume>83</volume><fpage>337</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">15948788</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amati-Bonneau</surname><given-names>P</given-names></name><name><surname>Valentino</surname><given-names>ML</given-names></name><name><surname>Reynier</surname><given-names>P</given-names></name><name><surname>Gallardo</surname><given-names>ME</given-names></name><name><surname>Bornstein</surname><given-names>B</given-names></name><name><surname>Boissi&#x000e8;re</surname><given-names>A</given-names></name><name><surname>Campos</surname><given-names>Y</given-names></name><name><surname>Rivera</surname><given-names>H</given-names></name><name><surname>de la Aleja</surname><given-names>JG</given-names></name><name><surname>Carroccia</surname><given-names>R</given-names></name><name><surname>Iommarini</surname><given-names>L</given-names></name><name><surname>Labauge</surname><given-names>P</given-names></name><name><surname>Figarella-Branger</surname><given-names>D</given-names></name><name><surname>Marcorelles</surname><given-names>P</given-names></name><name><surname>Furby</surname><given-names>A</given-names></name><name><surname>Beauvais</surname><given-names>K</given-names></name><name><surname>Letournel</surname><given-names>F</given-names></name><name><surname>Liguori</surname><given-names>R</given-names></name><name><surname>La Morgia</surname><given-names>C</given-names></name><name><surname>Montagna</surname><given-names>P</given-names></name><name><surname>Liguori</surname><given-names>M</given-names></name><name><surname>Zanna</surname><given-names>C</given-names></name><name><surname>Rugolo</surname><given-names>M</given-names></name><name><surname>Cossarizza</surname><given-names>A</given-names></name><name><surname>Wissinger</surname><given-names>B</given-names></name><name><surname>Verny</surname><given-names>C</given-names></name><name><surname>Schwarzenbacher</surname><given-names>R</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>MA</given-names></name><name><surname>Arenas</surname><given-names>J</given-names></name><name><surname>Ayuso</surname><given-names>C</given-names></name><name><surname>Garesse</surname><given-names>R</given-names></name><name><surname>Lenaers</surname><given-names>G</given-names></name><name><surname>Bonneau</surname><given-names>D</given-names></name><name><surname>Carelli</surname><given-names>V</given-names></name></person-group><article-title>OPA1 mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes.</article-title><source>Brain</source><year>2008</year><volume>131</volume><fpage>338</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">18158317</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jurka</surname><given-names>J</given-names></name><name><surname>Kapitonov</surname><given-names>VV</given-names></name><name><surname>Pavlicek</surname><given-names>A</given-names></name><name><surname>Klonowski</surname><given-names>P</given-names></name><name><surname>Kohany</surname><given-names>O</given-names></name><name><surname>Walichiewicz</surname><given-names>J</given-names></name></person-group><article-title>Repbase Update, a database of eukaryotic repetitive elements.</article-title><source>Cytogenet Genome Res</source><year>2005</year><volume>110</volume><fpage>462</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16093699</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mighell</surname><given-names>AJ</given-names></name><name><surname>Markham</surname><given-names>AF</given-names></name><name><surname>Robinson</surname><given-names>PA</given-names></name></person-group><article-title>Alu sequences.</article-title><source>FEBS Lett</source><year>1997</year><volume>417</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">9395063</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazazian</surname><given-names>HH</given-names><suffix>Jr</suffix></name></person-group><article-title>Mobile elements: drivers of genome evolution.</article-title><source>Science</source><year>2004</year><volume>303</volume><fpage>1626</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">15016989</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000e4;sler</surname><given-names>J</given-names></name><name><surname>Strub</surname><given-names>K</given-names></name></person-group><article-title>Alu elements as regulators of gene expression.</article-title><source>Nucleic Acids Res</source><year>2006</year><volume>34</volume><fpage>5491</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17020921</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>JM</given-names></name><name><surname>Stenson</surname><given-names>PD</given-names></name><name><surname>Cooper</surname><given-names>DN</given-names></name><name><surname>F&#x000e9;rec</surname><given-names>C</given-names></name></person-group><article-title>A systematic analysis of LINE-1 endonuclease-dependent retrotranspositional events causing human genetic disease.</article-title><source>Hum Genet</source><year>2005</year><volume>117</volume><fpage>411</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">15983781</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganguly</surname><given-names>A</given-names></name><name><surname>Dunbar</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Godmilow</surname><given-names>L</given-names></name><name><surname>Ganguly</surname><given-names>T</given-names></name></person-group><article-title>Exon skipping caused by an intronic insertion of a young Alu Yb9 element leads to severe hemophilia A.</article-title><source>Hum Genet</source><year>2003</year><volume>113</volume><fpage>348</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">12884004</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>MR</given-names></name><name><surname>Andersen</surname><given-names>LB</given-names></name><name><surname>Saulino</surname><given-names>AM</given-names></name><name><surname>Gregory</surname><given-names>PE</given-names></name><name><surname>Glover</surname><given-names>TW</given-names></name><name><surname>Collins</surname><given-names>FS</given-names></name></person-group><article-title>A de novo Alu insertion results in neurofibromatosis type 1.</article-title><source>Nature</source><year>1991</year><volume>353</volume><fpage>864</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">1719426</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tighe</surname><given-names>PJ</given-names></name><name><surname>Stevens</surname><given-names>SE</given-names></name><name><surname>Dempsey</surname><given-names>S</given-names></name><name><surname>Le Deist</surname><given-names>F</given-names></name><name><surname>Rieux-Laucat</surname><given-names>F</given-names></name><name><surname>Edgar</surname><given-names>JD</given-names></name></person-group><article-title>Inactivation of the Fas gene by Alu insertion: retrotransposition in an intron causing splicing variation and autoimmune lymphoproliferative syndrome.</article-title><source>Genes Immun</source><year>2002</year><volume>3</volume><fpage>S66</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">12215906</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lev-Maor</surname><given-names>G</given-names></name><name><surname>Ram</surname><given-names>O</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Sela</surname><given-names>N</given-names></name><name><surname>Goren</surname><given-names>A</given-names></name><name><surname>Levanon</surname><given-names>EY</given-names></name><name><surname>Ast</surname><given-names>G</given-names></name></person-group><article-title>Intronic Alus influence alternative splicing.</article-title><source>Plos&#x000a0;Genet</source><year>2008</year><volume>4</volume><fpage>e1000204</fpage><pub-id pub-id-type="pmid">12215906</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Gonder</surname><given-names>MK</given-names></name><name><surname>Azrak</surname><given-names>S</given-names></name><name><surname>Ray</surname><given-names>DA</given-names></name><name><surname>Batzer</surname><given-names>MA</given-names></name><name><surname>Tishkoff</surname><given-names>SA</given-names></name><name><surname>Liang</surname><given-names>P</given-names></name></person-group><article-title>Whole genome computational comparative genomics: A fruitful approach for ascertaining Alu insertion polymorphisms.</article-title><source>Gene</source><year>2006</year><volume>365</volume><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">16376498</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jurka</surname><given-names>J</given-names></name></person-group><article-title>Sequence patterns indicate an enzymatic involvement in integration of mammalian retroposons.</article-title><source>Proc Natl Acad Sci USA</source><year>1997</year><volume>94</volume><fpage>1872</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9050872</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toomes</surname><given-names>C</given-names></name><name><surname>Marchbank</surname><given-names>NJ</given-names></name><name><surname>Mackey</surname><given-names>DA</given-names></name><name><surname>Craig</surname><given-names>JE</given-names></name><name><surname>Newbury-Ecob</surname><given-names>RA</given-names></name><name><surname>Bennett</surname><given-names>CP</given-names></name><name><surname>Vize</surname><given-names>CJ</given-names></name><name><surname>Desai</surname><given-names>SP</given-names></name><name><surname>Black</surname><given-names>GCM</given-names></name><name><surname>Patel</surname><given-names>N</given-names></name><name><surname>Teimory</surname><given-names>M</given-names></name><name><surname>Markham</surname><given-names>AF</given-names></name><name><surname>Inglehearn</surname><given-names>CF</given-names></name><name><surname>Churchill</surname><given-names>AJ</given-names></name></person-group><article-title>Spectrum, frequency and penetrance of OPA1 mutations in dominant optic atrophy.</article-title><source>Hum Mol Genet</source><year>2001</year><volume>10</volume><fpage>1369</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">11440989</pub-id></mixed-citation></ref></ref-list></back></article>